ES2181771T3 - Composiciones de inhibina y metodo para el uso de la misma. - Google Patents

Composiciones de inhibina y metodo para el uso de la misma.

Info

Publication number
ES2181771T3
ES2181771T3 ES95913576T ES95913576T ES2181771T3 ES 2181771 T3 ES2181771 T3 ES 2181771T3 ES 95913576 T ES95913576 T ES 95913576T ES 95913576 T ES95913576 T ES 95913576T ES 2181771 T3 ES2181771 T3 ES 2181771T3
Authority
ES
Spain
Prior art keywords
protein
heterological
inhibine
heterology
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95913576T
Other languages
English (en)
Inventor
William C Fioretti
Konstantin Kousoulas
Daniel G Satterlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agritech Technologies Ltd
Louisiana State University
Original Assignee
Agritech Technologies Ltd
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agritech Technologies Ltd, Louisiana State University filed Critical Agritech Technologies Ltd
Application granted granted Critical
Publication of ES2181771T3 publication Critical patent/ES2181771T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN METODO PARA ACELERAR LA APARICION DE LA PUBERTAD EN AVIARES, ESPECIALMENTE EN RATITAS Y PSITACIFORMES, MEDIANTE LA ADMINISTRACION DE UNA PROTEINA HETEROLOGA QUE CONTENGA INHIBINA, O UN FRAGMENTO DE LA MISMA, Y UNA PROTEINA DE SOPORTE. LA PRESENTE INVENCION TAMBIEN SE REFIERE A UN METODO PARA AUMENTAR LA PRODUCCION DE HUEVOS EN ANIMALES, EN PARTICULAR PAJAROS, PARTICULARMENTE RATITAS, MEDIANTE LA ADMINISTRACION DE LA PROTEINA HETEROLOGA. ESTA INVENCION TAMBIEN SE REFIERE A LA PROTEINA HETEROLOGA Y A UN METODO PARA LA PRODUCCION DE LA PROTEINA HETEROLOGA. LA PROTEINA HETEROLOGA PUEDE SER BIEN INHIBINA CONJUGADA A LA PROTEINA DE SOPORTE O INHIBINA FUSIONADA A LA PROTEINA DE SOPORTE. EL METODO PARA LA PRODUCCION DE LA PROTEINA HETEROLOGA FUSIONADA CONSISTE EN INSERTAR UNA INHIBINA QUE CODIFICA UN CADN DE DOBLE CEPA, O UN FRAGMENTO DE LA MISMA, EN UN VECTOR QUE CODIFICA UNA PROTEINA DE SOPORTE TAL COMO UNA PROTEINA QUE SE ENLAZA A LA MALTOSA O ALBUMINA DEL SUERO BOVINO. TRAS INSERTAR EL VECTOR EN UN SISTEMA DE EXPRESION, EL SISTEMA EXPRESA LA PROTEINA HETEROLOGA FUSIONADA. TRAS PURIFICAR LA PROTEINA HETEROLOGA EXPRESADA, SE ADMINISTRA UNA CANTIDAD EFECTIVA DE LA PROTEINA A UN ANIMAL DE MODO QUE SE PRODUZCA UNA RESPUESTA INMUNOLOGICA EN EL ANIMAL CONTRA LA PROTEINA HETEROLOGA.
ES95913576T 1994-02-28 1995-02-28 Composiciones de inhibina y metodo para el uso de la misma. Expired - Lifetime ES2181771T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20296494A 1994-02-28 1994-02-28

Publications (1)

Publication Number Publication Date
ES2181771T3 true ES2181771T3 (es) 2003-03-01

Family

ID=22751927

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95913576T Expired - Lifetime ES2181771T3 (es) 1994-02-28 1995-02-28 Composiciones de inhibina y metodo para el uso de la misma.

Country Status (18)

Country Link
EP (1) EP0804219B1 (es)
JP (1) JPH09510702A (es)
CN (1) CN1149258A (es)
AT (1) ATE220554T1 (es)
AU (1) AU704737B2 (es)
BR (1) BR9507426A (es)
CA (1) CA2184183C (es)
DE (1) DE69527439T2 (es)
DK (1) DK0804219T3 (es)
ES (1) ES2181771T3 (es)
FI (1) FI963325L (es)
MX (1) MX9603702A (es)
NO (1) NO963572L (es)
NZ (1) NZ282981A (es)
PL (1) PL184202B1 (es)
PT (1) PT804219E (es)
RU (1) RU2170100C2 (es)
WO (1) WO1995022980A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786179A (en) * 1994-02-28 1998-07-28 Agritech Technologies Ltd. Heterologous protein comprising avian alpha-subunit inhibin protein and methods of producing same
US5725858A (en) * 1994-02-28 1998-03-10 Agritech Technologies, Ltd. Methods of enhancing production performance of birds comprising administration of heterologous protein comprising avian alpha-subunit inhibin protein
BR0316084A (pt) * 2002-11-07 2005-09-27 Agritech Technology Ltd Composições peptìdicas antigênicas múltiplas relacionadas com a inibina que melhoram o desempenho da produção avìcola.
EP3470072A1 (en) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
AU2006285850A1 (en) 2005-08-29 2007-03-08 Japan Science And Technology Agency Antibody produced using ostrich and method for production thereof
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
BR102014005376A2 (pt) * 2014-03-07 2016-02-10 Ouro Fino Saúde Animal Ltda antígeno de inibina alfa, gene codificante de inibina alfa, gene codificante de proteína de fusão, processo de obtenção do antígeno de inibina alfa, composição antigênica, uso do antígeno de inibina alfa e uso da composição antigênica
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
US11198867B2 (en) 2016-06-16 2021-12-14 Ionis Pharmaceuticals, Inc. Combinations for the modulation of SMN expression
CN110551744A (zh) * 2019-09-18 2019-12-10 普健生物(武汉)科技有限公司 一种人抑制素a的核苷酸序列及重组表达人抑制素a的方法
CN120505310A (zh) 2020-02-28 2025-08-19 Ionis制药公司 用于调节smn2的化合物和方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4864019A (en) * 1985-11-08 1989-09-05 The Salk Institute For Biological Studies Antibodies to inhibin and conjugates produced therefrom

Also Published As

Publication number Publication date
DE69527439D1 (de) 2002-08-22
PL316628A1 (en) 1997-02-03
ATE220554T1 (de) 2002-08-15
CA2184183C (en) 2005-02-08
NO963572D0 (no) 1996-08-27
CA2184183A1 (en) 1995-08-31
AU2095995A (en) 1995-09-11
EP0804219A4 (en) 1999-02-24
PT804219E (pt) 2002-12-31
FI963325A7 (fi) 1996-10-21
CN1149258A (zh) 1997-05-07
BR9507426A (pt) 1997-09-16
FI963325L (fi) 1996-10-21
FI963325A0 (fi) 1996-08-27
PL184202B1 (pl) 2002-09-30
AU704737B2 (en) 1999-05-06
NZ282981A (en) 1998-08-26
NO963572L (no) 1996-10-25
JPH09510702A (ja) 1997-10-28
RU2170100C2 (ru) 2001-07-10
DK0804219T3 (da) 2002-11-11
MX9603702A (es) 1997-12-31
EP0804219A1 (en) 1997-11-05
EP0804219B1 (en) 2002-07-17
WO1995022980A1 (en) 1995-08-31
DE69527439T2 (de) 2003-02-20

Similar Documents

Publication Publication Date Title
ES2181771T3 (es) Composiciones de inhibina y metodo para el uso de la misma.
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
Ajioka et al. Intracellular pools of transferrin receptors result from constitutive internalization of unoccupied receptors.
BR9913433A (pt) Sistema desinfetante estabilizado composto de duas partes e composições e métodos a ele relacionado
AR007249A1 (es) Preparacion concentrada de anticuerpos
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
PT971705E (pt) Formulacoes de farmacos de terapeutica de substituicao hormonal para aplicacao topica na pele
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
BR9906903A (pt) Composição com liberação sustentada, processos para produzir a mesma, para suprimir a brusca liberação inicial da susbtância bioativa de uma composição com liberação sustentada e para aumentar a eficiência da inclusão da substância bioativa em uma composição com liberação sustentada, produto farmacêutico, agente para prevenir ou tratar câncer prostático, hipertrofia prostática, endometriose, histeromioma, metrofibroma, puberdade precoce, dismenorréia, ou câncer do seio, ou um contraceptivo, e, composto
ES2080838T3 (es) Conjugados de anticuerpos especificos del receptor de transferrina y agentes neurofarmaceuticos.
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
BR9811094A (pt) Agente terapêutico para tumores linfáticos
PT1272199E (pt) Terapias de combinacao com actividade de lesao vascular
DE69925371D1 (de) Impfstoff für geflügel
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK1021534T3 (da) Hepatitis C-receptorprotein CD81
ES2061521T3 (es) Proteinas con actividad glutation-s-transferasa, secuencias de adn, anticuerpos, poxvirus y medicamentos para la prevencion de la equistosomiasis.
EA199901061A1 (ru) Новые соли врс-пептидов с органопротективной активностью, способ их получения и их использование в терапии
PT866861E (pt) Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina
JPS58501543A (ja) ヒトインタ−フエロン蛋白とヒトインタ−フエロン蛋白に対する抗体に関する改良
AR133834A1 (es) Agentes de penetración célular y sus usos
CR10676A (es) Agente para prevenir/ tratar el cancer
MX9704879A (es) Anticuerpo monoclonal novedoso que tiene actividad inhibidora contra fosfolipasa a2 de tipo ii y proteina que comprende una parte del mismo.
ECSP993219A (es) Anticuerpo humanizado especifico para el 4- ibb humano y composicion farmaceutica que comprende el mismo